Coria launches prescription Atralin anti-acne gel

FORT WORTH, Texas Coria Laboratories has launched its new drug, Atralin gel 0.05 percent. The drug is used to fight against the lesions of acne vulgaris.

In two separate 12-week studies, the drug was proven to be very successful in decreasing total acne lesions compared to a placebo. In the first study, 43 percent of the people using Atralin saw significance decrease in lesions compared to 22 percent using the placebo.

In the second study, 32 percent of the people using the placebo saw a decrease compared to 48 percent using Atralin.

“The new Atralin gel not only provides effective treatment but encourages patient compliance, which is often the key to keeping acne at bay and preventing any potential worsening or scarring,” said Duncan Aust, senior vice president of research and development, branded pharmaceuticals, at Coria Laboratories. “In addition to its proven efficacy, the low incidence of adverse events is expected to produce wide patient acceptance to achieve more favorable clinical outcomes.”